Iams Wealth Management LLC Purchases Shares of 410 Eli Lilly and Company (NYSE:LLY)

Iams Wealth Management LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 410 shares of the company’s stock, valued at approximately $311,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Vanguard Group Inc. grew its position in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Capital World Investors grew its position in Eli Lilly and Company by 0.3% in the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock valued at $15,709,466,000 after acquiring an additional 89,720 shares during the last quarter. Morgan Stanley lifted its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $5,992,890,000. Finally, Capital Research Global Investors grew its holdings in shares of Eli Lilly and Company by 4.5% in the fourth quarter. Capital Research Global Investors now owns 7,577,592 shares of the company’s stock worth $4,417,120,000 after purchasing an additional 325,342 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.8 %

Shares of NYSE:LLY opened at $906.71 on Wednesday. The business has a 50-day moving average price of $818.06 and a 200-day moving average price of $743.26. The stock has a market cap of $861.75 billion, a price-to-earnings ratio of 133.54, a PEG ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $916.83. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the firm earned $1.62 EPS. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on LLY shares. BMO Capital Markets boosted their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $915.26, for a total value of $53,770,609.74. Following the sale, the insider now owns 97,308,620 shares in the company, valued at approximately $89,062,687,541.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $915.26, for a total value of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares in the company, valued at $89,062,687,541.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 849,894 shares of company stock valued at $727,475,118 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.